Phase III of the COVACTA trial of Actemra/RoActemra did not meet its primary endpoint of improved clinical status in patients with COVID-19 pneumonia.
According to the Basel pharmaceutical company Roche, the COVACTA trial did not meet its primary endpoint, which included the difference in patients mortality at week four, which was not met. The study did not identify any new safety signals for Actemra. Further analysis of the trial results is needed to understand the data fully.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.